Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - PDL BIOPHARMA, INC. | ex99-1.htm |
| 8-K - FORM 8-K - PDL BIOPHARMA, INC. | pdlbio_8k-030812.htm |
Exhibit 99.2
Royalty Revenue by Product ($ in 000's) *
|
Avastin
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
23,215
|
-
|
-
|
-
|
23,215
|
|
2011
|
22,283
|
41,967
|
23,870
|
22,886
|
111,006
|
|
2010
|
16,870
|
44,765
|
29,989
|
24,922
|
116,547
|
|
2009
|
13,605
|
35,161
|
21,060
|
15,141
|
84,966
|
|
2008
|
9,957
|
30,480
|
19,574
|
12,394
|
72,405
|
|
2007
|
8,990
|
21,842
|
17,478
|
9,549
|
57,859
|
|
2006
|
10,438
|
15,572
|
15,405
|
12,536
|
53,952
|
|
Herceptin
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
25,702
|
-
|
-
|
-
|
25,702
|
|
2011
|
25,089
|
42,209
|
31,933
|
21,812
|
121,042
|
|
2010
|
23,402
|
38,555
|
27,952
|
25,441
|
115,350
|
|
2009
|
16,003
|
32,331
|
26,830
|
18,615
|
93,779
|
|
2008
|
14,092
|
34,383
|
28,122
|
20,282
|
96,880
|
|
2007
|
19,035
|
28,188
|
22,582
|
14,802
|
84,608
|
|
2006
|
15,142
|
19,716
|
21,557
|
20,354
|
76,769
|
|
Lucentis
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
10,791
|
-
|
-
|
-
|
10,791
|
|
2011
|
8,878
|
24,313
|
12,157
|
10,750
|
56,099
|
|
2010
|
7,220
|
19,091
|
10,841
|
8,047
|
45,198
|
|
2009
|
4,621
|
12,863
|
8,123
|
6,152
|
31,759
|
|
2008
|
3,636
|
11,060
|
7,631
|
4,549
|
26,876
|
|
2007
|
2,931
|
6,543
|
6,579
|
3,517
|
19,570
|
|
2006
|
-
|
-
|
289
|
3,335
|
3,624
|
|
Xolair
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
5,447
|
-
|
-
|
-
|
5,447
|
|
2011
|
4,590
|
7,621
|
5,916
|
5,823
|
23,949
|
|
2010
|
3,723
|
6,386
|
4,980
|
4,652
|
19,741
|
|
2009
|
2,665
|
5,082
|
4,085
|
3,722
|
15,553
|
|
2008
|
1,488
|
4,866
|
3,569
|
2,927
|
12,850
|
|
2007
|
1,684
|
3,942
|
3,332
|
2,184
|
11,142
|
|
2006
|
2,263
|
2,969
|
3,041
|
2,495
|
10,768
|
|
Tysabri
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
11,233
|
-
|
-
|
-
|
11,233
|
|
2011
|
9,891
|
10,796
|
11,588
|
11,450
|
43,725
|
|
2010
|
8,791
|
8,788
|
8,735
|
9,440
|
35,754
|
|
2009
|
6,656
|
7,050
|
7,642
|
8,564
|
29,912
|
|
2008
|
3,883
|
5,042
|
5,949
|
6,992
|
21,866
|
|
2007
|
839
|
1,611
|
2,084
|
2,836
|
7,370
|
|
2006
|
-
|
-
|
-
|
237
|
237
|
|
Actemra
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
1,700
|
-
|
-
|
-
|
1,700
|
|
2011
|
913
|
1,136
|
1,401
|
1,460
|
4,910
|
|
2010
|
1,587
|
237
|
315
|
688
|
2,827
|
|
2009
|
585
|
537
|
909
|
1,197
|
3,228
|
|
2008
|
44
|
-
|
146
|
369
|
559
|
|
2007
|
32
|
-
|
-
|
17
|
49
|
|
2006
|
-
|
-
|
-
|
-
|
-
|
* As reported to PDL by its licensees
Totals may not sum due to rounding
Reported Net Sales Revenue by Product ($ in 000's) *
|
Avastin
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
1,502,757
|
-
|
-
|
-
|
1,502,757
|
|
2011
|
1,597,461
|
1,582,705
|
1,581,095
|
1,469,994
|
6,231,255
|
|
2010
|
1,506,788
|
1,596,892
|
1,594,707
|
1,646,218
|
6,344,605
|
|
2009
|
1,345,487
|
1,295,536
|
1,439,730
|
1,514,053
|
5,594,806
|
|
2008
|
980,715
|
1,084,930
|
1,180,427
|
1,239,382
|
4,485,454
|
|
2007
|
678,068
|
746,587
|
797,013
|
875,084
|
3,096,752
|
|
2006
|
439,318
|
516,052
|
570,551
|
592,897
|
2,118,817
|
|
Herceptin
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
1,515,255
|
-
|
-
|
-
|
1,515,255
|
|
2011
|
1,391,568
|
1,559,975
|
1,642,898
|
1,432,771
|
6,027,211
|
|
2010
|
1,270,846
|
1,349,512
|
1,300,934
|
1,409,310
|
5,330,602
|
|
2009
|
1,210,268
|
1,133,993
|
1,226,435
|
1,278,626
|
4,849,323
|
|
2008
|
1,105,426
|
1,195,215
|
1,211,982
|
1,186,806
|
4,699,428
|
|
2007
|
891,761
|
949,556
|
979,602
|
1,015,033
|
3,835,952
|
|
2006
|
529,585
|
659,719
|
761,099
|
803,576
|
2,753,979
|
|
Lucentis
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
1,079,092
|
-
|
-
|
-
|
1,079,092
|
|
2011
|
887,757
|
943,418
|
1,052,809
|
1,075,015
|
3,958,999
|
|
2010
|
721,967
|
698,890
|
745,376
|
804,684
|
2,970,917
|
|
2009
|
462,103
|
469,736
|
555,296
|
615,212
|
2,102,347
|
|
2008
|
363,615
|
393,682
|
460,167
|
454,922
|
1,672,386
|
|
2007
|
224,820
|
219,579
|
299,995
|
322,300
|
1,066,695
|
|
2006
|
-
|
-
|
10,689
|
157,742
|
168,431
|
|
Xolair
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
310,234
|
-
|
-
|
-
|
310,234
|
|
2011
|
267,754
|
277,642
|
310,874
|
314,911
|
1,171,182
|
|
2010
|
228,859
|
225,878
|
251,055
|
263,389
|
969,179
|
|
2009
|
184,669
|
181,086
|
211,006
|
219,693
|
796,454
|
|
2008
|
137,875
|
169,521
|
177,179
|
183,753
|
668,329
|
|
2007
|
129,172
|
130,700
|
144,250
|
147,754
|
551,876
|
|
2006
|
95,241
|
99,354
|
112,608
|
118,002
|
425,204
|
|
Tysabri
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
374,430
|
-
|
-
|
-
|
374,430
|
|
2011
|
329,696
|
356,876
|
388,758
|
381,618
|
1,456,948
|
|
2010
|
293,047
|
287,925
|
293,664
|
316,657
|
1,191,292
|
|
2009
|
221,854
|
229,993
|
257,240
|
285,481
|
994,569
|
|
2008
|
129,430
|
163,076
|
200,783
|
233,070
|
726,359
|
|
2007
|
30,468
|
48,715
|
71,972
|
94,521
|
245,675
|
|
2006
|
-
|
-
|
-
|
7,890
|
7,890
|
|
Actemra
|
Q1
|
Q2
|
Q3
|
Q4
|
Total
|
|
2012
|
56,662
|
-
|
-
|
-
|
56,662
|
|
2011
|
30,433
|
35,370
|
46,709
|
48,671
|
161,183
|
|
2010
|
52,908
|
5,405
|
10,493
|
22,919
|
91,725
|
|
2009
|
19,504
|
17,920
|
30,313
|
39,888
|
107,625
|
|
2008
|
1,452
|
1,377
|
5,981
|
12,305
|
21,115
|
|
2007
|
-
|
-
|
-
|
1,137
|
1,137
|
|
2006
|
-
|
-
|
-
|
-
|
-
|
* As reported to PDL by its licensees
Totals may not sum due to rounding
Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *
|
Avastin Sales
|
2010 - Q4
|
2011 - Q1
|
2011 - Q2
|
2011 - Q3
|
2011 - Q4
|
2012 - Q1
|
|
US Made & Sold
|
800,139
|
708,539
|
719,967
|
688,966
|
684,878
|
652,824
|
|
US Made & ex-US Sold
|
415,576
|
580,981
|
548,710
|
587,975
|
375,830
|
448,037
|
|
ex-US Made & Sold
|
430,503
|
307,941
|
314,028
|
304,155
|
409,286
|
401,896
|
|
Total
|
1,646,218
|
1,597,461
|
1,582,705
|
1,581,095
|
1,469,994
|
1,502,757
|
|
US Made & Sold
|
49%
|
44%
|
45%
|
44%
|
47%
|
43%
|
|
US Made & ex-US Sold
|
25%
|
36%
|
35%
|
37%
|
26%
|
30%
|
|
ex-US Made & Sold
|
26%
|
19%
|
20%
|
19%
|
28%
|
27%
|
|
Herceptin Sales
|
2010 - Q4
|
2011 - Q1
|
2011 - Q2
|
2011 - Q3
|
2011 - Q4
|
2012 - Q1
|
|
US Made & Sold
|
416,611
|
409,854
|
442,903
|
445,395
|
453,168
|
456,920
|
|
US Made & ex-US Sold
|
425,303
|
423,053
|
642,670
|
495,086
|
612,908
|
523,353
|
|
ex-US Made & Sold
|
567,396
|
558,661
|
474,402
|
702,416
|
366,695
|
534,982
|
|
Total
|
1,409,310
|
1,391,568
|
1,559,975
|
1,642,898
|
1,432,771
|
1,515,255
|
|
US Made & Sold
|
30%
|
29%
|
28%
|
27%
|
32%
|
30%
|
|
US Made & ex-US Sold
|
30%
|
30%
|
41%
|
30%
|
43%
|
35%
|
|
ex-US Made & Sold
|
40%
|
40%
|
30%
|
43%
|
26%
|
35%
|
|
Lucentis Sales
|
2010 - Q4
|
2011 - Q1
|
2011 - Q2
|
2011 - Q3
|
2011 - Q4
|
2012 - Q1
|
|
US Made & Sold
|
360,911
|
378,451
|
409,674
|
422,335
|
428,884
|
433,428
|
|
US Made & ex-US Sold
|
443,773
|
509,307
|
533,745
|
630,474
|
646,131
|
645,665
|
|
ex-US Made & Sold
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Total
|
804,684
|
887,757
|
943,418
|
1,052,809
|
1,075,015
|
1,079,092
|
|
US Made & Sold
|
45%
|
43%
|
43%
|
40%
|
40%
|
40%
|
|
US Made & ex-US Sold
|
55%
|
57%
|
57%
|
60%
|
60%
|
60%
|
|
ex-US Made & Sold
|
0%
|
0%
|
0%
|
0%
|
0%
|
0%
|
|
Xolair Sales
|
2010 - Q4
|
2011 - Q1
|
2011 - Q2
|
2011 - Q3
|
2011 - Q4
|
2012 - Q1
|
|
US Made & Sold
|
170,001
|
164,621
|
167,608
|
184,837
|
188,728
|
185,505
|
|
US Made & ex-US Sold
|
-
|
-
|
-
|
-
|
-
|
-
|
|
ex-US Made & Sold
|
93,388
|
103,133
|
110,034
|
126,037
|
126,184
|
124,729
|
|
Total
|
263,389
|
267,754
|
277,642
|
310,874
|
314,911
|
310,234
|
|
US Made & Sold
|
65%
|
61%
|
60%
|
59%
|
60%
|
60%
|
|
US Made & ex-US Sold
|
0%
|
0%
|
0%
|
0%
|
0%
|
0%
|
|
ex-US Made & Sold
|
35%
|
39%
|
40%
|
41%
|
40%
|
40%
|
|
Total Sales
|
2010 - Q4
|
2011 - Q1
|
2011 - Q2
|
2011 - Q3
|
2011 - Q4
|
2012 - Q1
|
|
US Made & Sold
|
1,747,662
|
1,661,465
|
1,740,152
|
1,741,534
|
1,755,657
|
1,728,678
|
|
US Made & ex-US Sold
|
1,284,652
|
1,513,340
|
1,725,125
|
1,713,535
|
1,634,869
|
1,617,054
|
|
ex-US Made & Sold
|
1,091,287
|
969,735
|
898,464
|
1,132,608
|
902,165
|
1,061,607
|
|
Total
|
4,123,601
|
4,144,540
|
4,363,741
|
4,587,677
|
4,292,691
|
4,407,339
|
|
US Made & Sold
|
42%
|
40%
|
40%
|
38%
|
41%
|
39%
|
|
US Made & ex-US Sold
|
31%
|
37%
|
40%
|
37%
|
38%
|
37%
|
|
ex-US Made & Sold
|
26%
|
23%
|
21%
|
25%
|
21%
|
24%
|
* As reported to PDL by its licensees
Totals may not sum due to rounding